Anti-CCL2 [CNTO 888 (Carlumab)]

Absolute Antibody

Anti-CCL2 [CNTO 888 (Carlumab)]

7

CCL2 is implicated in the pathogenesis of certain inflammatory diseases and cancer. Binding of CCL2 to its receptor CCR2 triggers calcium mobilization and chemotaxis. CNTO 888 is a neutralizing anti-CCL2 antibody that binds human CCL2 with high affinity of Kd=22pM and inhibits CCL2 binding to its receptor. The systemic administration of anti-CCL2 neutralizing antibodies (CNTO888 and C1142) significantly retarded tumor growth and attenuated CD68+ macrophage infiltration, which was accompanied by a significant decrease in microvascular density (PMID: 17710158). Phase 1 trials in 44 patients with solid tumors concluded that CNTO888 was well tolerated in individuals with evidence of transient free CCL2 suppression and preliminary antitumor activity (PMID: 23385782). This antibody was also capable of inhibiting growth of breast cancer when administered individually or as a cocktail (Campion et al, 2009). A phase 2 study in 46 patients with castration-resistant prostate cancer (CRPC) concluded that carlumab was well-tolerated but did not block the CCL2/CCR2 axis or show antitumor activity as a single agent in metastatic CRPC (PMID: 22907596).

Neutralisation/Blocking

Inhibit; Block; Therapeutic

Research Use Only

Monoclonal

CNTO 888 (Carlumab)

CCL2

C-C motif chemokine ligand 2

C-C motif chemokine 2; chemokine (C-C motif) ligand 2; GDCF-2; HC11; HSMCR30; MCAF; MCP1; MCP-1; monocyte chemoattractant protein-1; monocyte chemotactic and activating factor; monocyte chemotactic protein 1; monocyte secretory protein JE; SCYA2; small inducible cytokine A2 (monocyte chemotactic protein 1, homologous to mouse Sig-je); small inducible cytokine subfamily A (Cys-Cys), member 2; small-inducible cytokine A2; SMC-CF

Human

IgG1

C-C motif chemokine 2

Human

The original antibody was generated by phage display using the Human Combinatorial Antibody Library (HuCAL GOLD).

-20°C,2°C to 8°C

12352203